Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $19.33

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $19.33.

Several research analysts have issued reports on VYGR shares. HC Wainwright started coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price objective for the company. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Citigroup started coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Guggenheim started coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target for the company.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $8.57 on Monday. The business has a 50 day simple moving average of $8.85 and a 200-day simple moving average of $8.03. The stock has a market capitalization of $466.12 million, a PE ratio of 2.77 and a beta of 0.98. Voyager Therapeutics has a 12 month low of $6.06 and a 12 month high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $1.84. The firm had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. As a group, equities research analysts anticipate that Voyager Therapeutics will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SummerHaven Investment Management LLC raised its position in shares of Voyager Therapeutics by 1.9% in the fourth quarter. SummerHaven Investment Management LLC now owns 74,146 shares of the company’s stock valued at $626,000 after buying an additional 1,367 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Voyager Therapeutics by 0.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock valued at $1,495,000 after acquiring an additional 1,455 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Voyager Therapeutics by 2.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after purchasing an additional 2,030 shares during the period. Ritholtz Wealth Management boosted its holdings in shares of Voyager Therapeutics by 11.8% during the fourth quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock worth $167,000 after purchasing an additional 2,089 shares during the last quarter. Finally, Empowered Funds LLC grew its position in shares of Voyager Therapeutics by 8.2% in the first quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock valued at $367,000 after purchasing an additional 2,975 shares during the period. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.